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Objective: Dyspnea is a defining symptom in the classification and treatment of chronic 
obstructive pulmonary disease (COPD). However, the degree of variation in burden among 
symptomatic COPD patients and the possible correlates of burden remain unclear. This study 
was conducted to characterize patients in Europe currently being treated for COPD according 
to the level of dyspnea in terms of sociodemographics, health-related quality of life, work pro-
ductivity impairment, and health care resource use assessed by patient reports.
Methods: Data were derived from the 5-EU 2013 National Health and Wellness Survey 
(N=62,000). Respondents aged $40 years who reported currently using a prescription for 
COPD were grouped according to their level of dyspnea as per the Global Initiative for Chronic 
Obstructive Lung Disease guidelines and compared on health status (revised Short Form 36 
[SF-36]v2), work impairment (Work Productivity and Activity Impairment questionnaire), and 
number of health care visits in the past 6 months using generalized linear models with appropri-
ate distributions and link functions.
Results: Of the 768 respondents who met the inclusion criteria, 245 (32%) were considered 
to have higher dyspnea (equivalent to modified Medical Research Council score $2). Higher 
dyspnea was associated with decrements ranging from 3.9 to 8.2 points in all eight domains of 
the SF-36 health profile after adjustment for sociodemographics, general health characteristics, 
and length of COPD diagnosis; mental component summary scores and Short Form-6D health 
utility scores were lower by 3.5 and 0.06 points, respectively. Adjusted mean activity impair-
ment (55% vs 37%, P,0.001) and number of emergency room visits (0.61 vs 0.40, P=0.030) 
were higher in patients with greater dyspnea.
Conclusion: Many European patients with COPD continue to experience dyspnea despite 
treatment and at levels associated with notable impairments in the patients’ ability to function 
across a multitude of domains. These patients may benefit from more intense treatment of 
their symptoms.
Keywords: COPD, dyspnea, health-related quality of life, activity impairment, symptoms
Introduction
Patients with chronic obstructive pulmonary disease (COPD) experience significant 
overall symptom burden, comparable to that observed in patients diagnosed with 
cancer.1 This symptom burden can be associated with impairments in health-related 
quality of life (HRQoL),2–4 impaired functioning,5,6 and higher direct7 and indirect 
costs.7–9 COPD treatments have shown effectiveness in reducing breathlessness and 
improving HRQoL.10–17 However, some patients continue to experience dyspnea 
despite treatment.18,19 Moreover, this is critical given that recent studies suggest that 
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the COPD-associated burden is increasing globally and costs 
are increasing in tandem.20,21 The European Lung White 
Book estimates that, COPD is responsible for 150,000 deaths 
and 1,691,000 disability-adjusted life years lost in Europe, 
thus reinforcing the tremendous burden that COPD exerts 
on society at large.22 In Europe, COPD is estimated to be 
responsible for €48.4 billion in health care costs and lost 
productivity each year, including an estimated €25.1 billion 
in indirect costs alone.22
Of all the symptoms of COPD, dyspnea is the most 
dominant and defining one.1 Dyspnea is defined as a sub-
jective experience of breathing discomfort that consists of 
qualitatively distinct sensations that vary in intensity.23 The 
discomfort associated with dyspnea has been shown to affect 
HRQoL and health status.24–27 In recognition of the prominent 
role of dyspnea in the assessment and management of COPD, 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) strategy recommends the use of patient-reported 
severity of dyspnea as part of the patient classification sys-
tem. The international group recommends the routine use of 
screening measures, such as the COPD Assessment Test28 
or the modified Medical Research Council (mMRC)29 scale, 
to assess dyspnea among patients. Such assessments require 
individuals to report the degree of activity that results in 
breathlessness (eg, walking up a flight of stairs) and correlate 
well with health status30 and longer assessment measures.31
Despite the importance of self-reported dyspnea in the 
classification and treatment of COPD, the degree of variation 
in burden in patients with symptomatic COPD and the possible 
correlates of burden remain unclear. This is particularly true 
on an international level, whereby there exists a paucity of 
large-scale representative studies. The aim of this study was 
to characterize patients in Europe currently being treated for 
COPD according to their level of dyspnea in terms of socio-
demographics, HRQoL, work productivity impairment, and 
health care resource use assessed by patient reports.
Methods
study population
Data were derived from the 5-EU 2013 National Health and 
Wellness Survey (NHWS; N=62,000). The survey sample 
was representative of adults in France, Germany, Italy, Spain, 
and the UK, in terms of age and gender; all the data were 
self-reported. The protocol for the NHWS was reviewed and 
approved by Essex Institutional Review Board (Lebanon, 
NJ, USA; protocol number KH-NHES-EU13), and all 
respondents provided informed consent. In the current study, 
respondents aged $40 years and currently receiving prescrip-
tion medication for COPD, emphysema, and/or chronic bron-
chitis (hereafter referred to as COPD) were included. Patients 
with asthma were excluded from the selected group to ensure 
that dyspnea was a symptom of COPD in the respondents 
rather than attributable to asthma.
Participants were categorized into lower and higher dys-
pnea groups using an item based on the mMRC scale and the 
GOLD categorization (mMRC levels 0–1 vs $2; see Table 1 
for the exact statements).
study outcomes
Sociodemographic and health characteristics included age, 
gender, body mass index (BMI), current smoking status, and 
years since COPD diagnosis. The NHWS asks respondents 
to indicate the conditions they have been diagnosed with 
from a list of conditions, and these were used to calculate 
Table 1 Dyspnea measurement used in gOlD guidelines and the current study
GOLD 
classification
mMRC wordinga Current study wording Analysis group
less symptoms 0: I only get breathless with strenuous exercise I only get breathless after strenuous exercise lower dyspnea
I get breathless after moderate exercise
1: I get short of breath when hurrying on level 
ground or walking up a slight hill
I get breathless when hurrying on level 
ground or walking up a slight incline
More symptoms 2: On level ground, I walk slower than people of 
the same age because of breathlessness, or have 
to stop for breath when walking at my own pace
I walk slower than most people my age due 
to my breathing
higher dyspnea
I sometimes have to stop for breath even 
when walking on level ground at my own pace
3: I stop for breath after walking about 100 yards 
or after a few minutes on level ground
I stop for breath every few minutes while 
walking, even on level ground
4: I am too breathless to leave the house or I am 
breathless when dressing
I am too breathless to leave the house
none of the above excluded
Note: amMrC scale is used with the permission of the Medical research Council.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.
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the Charlson Comorbidity Index (CCI).32 Health status of 
respondents was assessed through the revised Short Form-36 
health questionnaire (SF-36)v2.33 This instrument is designed 
to report on eight health concepts (physical functioning, role 
physical, bodily pain, general health, vitality, social func-
tioning, role emotional, and mental health). Two summary 
scores were also calculated: physical component summary 
(PCS) and mental component summary (MCS) scores. The 
current study used the standard norm-based scores for both 
the individual health concept scores and the two-component 
summary scores as calculated by the scoring software pro-
vided by the scale developer. These scores have a mean of 
50 and a standard deviation (SD) of 10 for the US population 
(no pan-European norms are available for scoring, and scores 
based on the US norms are commonly presented regardless of 
country).33 Higher scores indicate better HRQoL. The SF-6D 
preference-based health utility was also calculated from 
the responses to the SF-36v2 using UK general population 
values.34 The SF-6D index has interval scoring properties 
and yields summary scores on a theoretical scale of 0–1, with 
1 indicating full health.
Impairment in work and non-work daily activities due 
to health in the past 7 days was assessed using the General 
Health version of the Work Productivity and Activity Impair-
ment questionnaire.35 Employed respondents provided data 
for absenteeism (percentage of work time missed), presentee-
ism (percentage of impairment while at work), and overall 
work productivity loss (an estimate that combines absentee-
ism and presenteeism). All respondents indicated their level 
of activity impairment (percentage of impairment in daily 
activities because of health; this refers to non-work activities 
and does not specifically refer to physical activity).
Health care resource use was captured by the number 
of health care provider (HCP) visits, emergency room (ER) 
visits, and hospitalizations in 6 months prior to the survey.
analyses
Lower and higher dyspnea groups were compared on socio-
demographic characteristics, general health characteristics, 
length of COPD diagnosis, and outcomes by using an 
independent sample t-test for continuous variables and the 
chi-square test for categorical variables.
Subsequently, a series of regression analyses were con-
ducted to compare the outcomes of the two dyspnea groups 
while adjusting for covariates. Covariates included country, 
age (as a continuous variable), gender, marital status (mar-
ried or living with partner vs not married), completion of a 
university degree (yes or no), employment status (full-time, 
part-time, or self-employed vs unemployed), household 
income (median split within country), BMI category (under-
weight, normal weight, overweight, obese, or decline to 
answer), smoking (current smoker, former smoker, or never 
smoked cigarettes), alcohol use (any vs none), exercise (self-
reported as the number of days in the past month with vigor-
ous exercise for $20 minutes; coarsened to 0 vs $1 day), CCI 
(continuous), and length of COPD diagnosis (continuous).
Linear models were used for HRQoL outcomes, and gen-
eralized linear models with a negative binomial distribution 
and a log-link function were used for outcomes that were not 
normally distributed, including work and activity impairment 
as well as health care resource use.
Results
A total of 768 respondents met the inclusion criteria, of 
whom 245 (32%) were categorized in the higher dyspnea 
group. Those in the higher dyspnea group were less 
likely to be employed (P=0.004), more likely to be obese 
(BMI $30 kg/m2; P=0.005), less likely to have exercised 
in the previous month (P,0.001), and had slightly higher 
CCI scores (P=0.012) relative to the respondents with lower 
dyspnea (Table 2).
HRQoL was worse among patients with higher dyspnea 
than among those with lower dyspnea (Figure 1A). Every 
domain and summary score calculated from the SF-36v2 was 
lower in patients with higher dyspnea (all P,0.001). The 
mean PCS score was 8.4 points lower and the mean MCS 
score was 4.1 points lower in patients with higher dyspnea. 
The mean health utility score was lower by 0.07 points in 
patients with higher dyspnea.
No significant differences in work impairment were 
observed between patients with higher and lower dyspnea 
(Table 3). Higher dyspnea was associated with a significantly 
greater mean impairment in (non-work) daily activities 
(65% vs 42%, P,0.001). The difference in the number 
of HCP visits did not reach significance (P=0.08). No 
statistically significant difference was observed in ER visits 
or hospitalizations.
Multivariable results
There were statistically significant decrements in all eight 
domains of the SF-36 health profile in the patients with higher 
dyspnea after adjustment for sociodemographics, general 
health characteristics, and length of COPD (Figure 1B). 
Adjusted differences between groups ranged from 3.9 points 
for mental health to 8.2 points for the physical function-
ing subscale. The adjusted mean PCS score was lower by 
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
940
gruenberger et al
Table 2 Characteristics of respondents according to the level of dyspnea
Variables Lower dyspnea (n=523) Higher dyspnea (n=245) P-value
Country (%)
France 13.8 14.3 0.206
germany 38.0 32.2
UK 21.6 27.3
Italy 13.4 15.9
spain 13.2 10.2
age in years, mean (sD) 61.39 (9.78) 62.65 (9.03) 0.089
Female (%) 41.1 42.4 0.725
Married/living with partner (%) 67.5 58.0 0.010
University degree (%) 30.2 24.5 0.101
employed (%) 34.4 24.1 0.004
household income (%)
Below median 61.4 63.7 0.828
above median 29.6 27.8
Decline to answer 9.0 8.6
BMI categories (%)
Underweight (,18.5 kg/m2) 2.9 1.6 0.005
normal (18.5 to ,25 kg/m2) 33.7 28.6
Overweight (25 to ,30 kg/m2) 38.8 31.8
Obese ($30 kg/m2) 23.9 36.3
Decline to answer 0.8 1.6
smoking status (%)
Current 40.0 34.3 0.016
Former 41.5 52.2
never 18.5 13.5
Drinks alcohol (%) 72.5 68.6 0.266
exercise in past 30 days (%) 46.5 30.6 ,0.001
CCI, mean (sD) 1.76 (1.26) 2.03 (1.71) 0.012
length of diagnosis in years, mean (sD) 10.28 (11.80) 11.58 (11.84) 0.158
Note: P-value is calculated from the independent-samples t-test for the difference between means and from the chi-square test for the differences in proportion.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; sD, standard deviation.
6.9 points, whereas the adjusted mean MCS score was lower 
by 3.5 points. After adjustment, SF-6D health utilities were 
0.06 points lower in higher dyspnea patients than in lower 
dyspnea patients.
Activity impairment was considerably greater among 
patients with higher dyspnea after adjustment (P,0.001). 
Consistent with the unadjusted results, differences in 
regression-adjusted work impairment did not reach statistical 
significance (all P.0.05; Table 4). Total HCP visits and hos-
pitalizations did not differ according to the level of dyspnea 
in unadjusted comparisons, although regression indicated 
an association of greater dyspnea with more self-reported 
ER visits (P,0.05).
Discussion
In the current study, approximately one in three patients cur-
rently using a prescription medication for COPD reported 
levels of dyspnea consistent with symptomatic COPD 
according to GOLD strategy (mMRC $2). More severe 
self-reported dyspnea was associated with significant impair-
ments in general HRQoL and work productivity, and these 
decrements in HRQoL exceeded the 5-point threshold gener-
ally considered as the minimally important difference (MID) 
for general health, physical functioning, role emotional, role 
physical, and social functioning components of the 8-factor 
health profile. In addition, both the MCS and PCS scores 
exceeded the MID of 3 points, with adjusted difference in 
PCS score being more than twice the MID.33 Impairment in 
daily activities was also markedly greater among patients 
with higher dyspnea, by 18% in absolute terms, and nearly 
50% in relative terms. Finally, those with higher dyspnea 
also reported higher rates of ER visits compared to those 
with lower dyspnea after adjustment for covariates.
The proportion of patients with significant dyspnea 
observed in this study is comparable or slightly lower than 
that in the European countries included in the Continuing to 
Confront COPD survey.36 This survey included respondents 
not using a prescription for COPD and did not exclude 
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
941
Dyspnea and quality of life in europe
Table 3 Work impairment and health care use by the level of dyspnea
Lower dyspnea (n=523) Higher dyspnea (n=245) P-value
Mean (SD) Mean (SD)
Work impairment, % (n = l and h dyspnena)
absenteeism (178 and 58) 12.5 (26.5) 13.9 (26.1) 0.732
Presenteeism (168 and 56) 31.9 (29.6) 38.0 (27.9) 0.170
Overall work impairment (178 and 58) 37.7 (34.1) 43.7 (32.8) 0.240
activity impairment (%) 42.3 (31.3) 64.8 (27.1) ,0.001
health care use (prior to 6 months)
hCP visits 9.0 (8.41) 10.20 (9.52) 0.082
er visits 0.39 (1.57) 0.50 (1.33) 0.326
hospitalizations 0.27 (0.68) 0.36 (0.84) 0.112
Abbreviations: er, emergency room; h, higher; hCP, health care provider; l, lower; sD, standard deviation.
Figure 1 (A) Functional health status and health utility scores by the level of dyspnea (unadjusted). (B) Functional health status and health utility by the level of dyspnea 
after regression adjustment.
Notes: *P,0.01; **P,0.001.
Abbreviations: BP, bodily pain; gh, general health; MCs, mental component summary; Mh, mental health; PCs, physical component summary; PF, physical functioning; 
re, role emotional; rP, role physical; sF, social functioning; sF-6D, short Form-6D health utility; VT, vitality.
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
942
gruenberger et al
individuals with comorbid asthma, suggesting that it could 
have included some individuals whose dyspnea would have 
been resolved with medication or may be attributable to 
asthma. These new data suggest that the high rate of dyspnea 
among COPD patients is present despite treatment and is not 
attributable to asthma.
Our findings also provide further confirmation of the 
relationship between dyspnea and HRQoL. A recent study 
has shown that dyspnea can be a strong predictor of mental 
and physical outcome components of HRQoL, even more so 
than the objective measures of lung functioning.37 Indeed, a 
meta-analysis of the correlation between factors associated 
with disease-specific HRQoL as measured by the St George’s 
Respiratory Questionnaire among COPD patients indicated 
dyspnea as one of the key correlates of HRQoL,38 and the 
general relationship between dyspnea and HRQoL has been 
demonstrated in a variety of studies ranging from longitudinal 
studies incorporating interviewer-administered scales39 as 
well as the mMRC and other self-report scales.25,40–42 A par-
ticular contribution of the current study is the assessment of 
the relationship between dyspnea and the full 8-factor health 
profile of the SF-36v2, in addition to the more commonly 
reported summary measures derived from the instrument. 
The generic, rather than disease-specific, nature of the 
SF-36v2 also provides measures that can be compared across 
conditions, providing context to the nature and extent of the 
impairment relative to other diseases.
The demographic characteristics of patients with COPD 
did not differ markedly based on severity of dyspnea, although 
individuals who reported higher levels of dyspnea tended to 
be more often obese and were less likely to be currently 
employed. As such, the decrements in outcomes associated 
with dyspnea observed in the unadjusted comparisons are not 
likely to be due to group differences in personal character-
istics. The groups continued to differ after adjustments for 
a broad range of sociodemographic and health characteristics, 
including BMI, comorbid medical conditions, and exercise, 
but as weight gain and lack of exercise may actually be the 
result of lower levels of physical activity due to dyspnea, the 
adjusted comparisons may be overly conservative.
Limitations
While the current study provides important insight into the 
experience of COPD sufferers in Europe using a large-scale 
representative survey, it is important to note the study limita-
tions. The cross-sectional design of this study did not allow 
for causal attributions, although it seems much more likely 
that dyspnea is responsible for the decrements in HRQoL 
than vice versa, and the relationship between dyspnea and 
HRQoL remained after controlling for covariates. Likewise, 
previous longitudinal research suggests dyspnea leads to 
lower HRQoL across multiple domains.39 Furthermore, 
the survey methodology employed did not enable patients’ 
diagnosis of COPD to be confirmed, nor was information 
on patients’ treatment history or objective measures of lung 
functioning available. It is also possible that some of the 
dyspnea experienced by patients is attributable to conditions 
other than COPD, such as congestive heart failure, though 
congestive heart failure was reported by a small minority of 
the respondents (11% and 4% of those with and without dys-
pnea, respectively; data not presented) and was included in 
the regression analysis through the CCI. These limitations, as 
well as the possible recall bias among the study participants, 
suggest caution in drawing firm conclusions.
Conclusion
The findings of this study highlight the need for a complete 
assessment of dyspnea in patients with COPD. This is impor-
tant, as this symptom is associated with notable impairments 
in the patients’ ability to function across a multitude of 
Table 4 regression-adjusted impairment and health care use by the level of dyspnea
Lower dyspnea (n=523) Higher dyspnea (n=245) P-value
Mean SE Mean SE
Work impairment
absenteeism (%) 6.1 3.0 7.9 4.7 0.562
Presenteeism (%) 25.5 5.2 35.0 8.1 0.055
Overall work impairment (%) 31.6 6.3 40.3 9.0 0.118
activity impairment (%) 36.8 2.5 54.7 4.2 ,0.001
health care use (prior to 6 months)
hCP visits 8.0 0.7 8.4 0.9 0.438
er visits 0.40 0.09 0.61 0.16 0.030
hospitalizations 0.00 0.00 0.00 0.00 0.538
Abbreviations: er, emergency room; hCP, health care provider; se, standard error of the mean.
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HRQoL domains. This is especially important in the context 
of patients with COPD because, many European patients in the 
current study continued to experience dyspnea despite being 
treated with a prescription medication for it. The results of this 
study suggest that many patients experience higher levels of 
dyspnea despite treatment and that additional therapies and/or 
more intense treatment regimens should be considered.
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